A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1−SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY

Trial Profile

A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1−SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms IMmotion010
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 02 Jun 2017 The planned analysis will occur when at least = 65% of pts in the 2 populations (renal cell carcinoma (RCC) patients (pts) at high risk of recurrence or have had complete resection of limited metachronous/synchronous metastasis) have died as per trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 15 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top